Antibiotic Consumption in Kazakhstan (2019-2023)
Author Information
Author(s): Semenova Yuliya, Yergaliyeva Ademi, Aimurziyeva Ainur, Manatova Almira, Kuntuganova Anargul, Makalkina Larissa, Aldiyarova Nurgul, Semenov Daniil, Lim Lisa, Figueras Albert
Primary Institution: Nazarbayev University
Hypothesis
This study aimed to provide a nationwide evaluation of antibiotic consumption in Kazakhstan during the period 2019–2023.
Conclusion
The study found a declining trend in antibiotic consumption in Kazakhstan, which is crucial for improving the national antimicrobial stewardship program.
Supporting Evidence
- The consumption of J01 antibiotics ranged between 10.869 DIDs (2022) and 14.470 DIDs (2020).
- Azithromycin was the most consumed systemic antibiotic, followed by ceftriaxone and ciprofloxacin.
- The number of people consuming the top five 'Watch' group antibiotics rose from 72,578 in 2019 to 94,617 in 2023.
- The overall trend in antibiotic consumption was declining, with an AAPC of −2.45%.
Takeaway
The study looked at how much antibiotics people in Kazakhstan used from 2019 to 2023 and found that overall use is going down, which is good for health.
Methodology
The study calculated defined daily doses per 1000 inhabitants per day for systemic antibiotics using data from a pharmaceutical market research company.
Limitations
The study only covered a five-year period and did not analyze factors contributing to the rise in antibiotic consumption during the COVID-19 pandemic.
Participant Demographics
The study evaluated antibiotic consumption across the entire healthcare sector in Kazakhstan.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website